Case. Fungal infections for the community provider. Case. Case. April 25, 2014 Peter V. Chin-Hong M.D. Infectious Diseases UCSF UCSF
|
|
- Kory Daniels
- 6 years ago
- Views:
Transcription
1 Case Fungal infections for the community provider April 25, 2014 Peter V. Chin-Hong M.D. Infectious Diseases UCSF UCSF A 38-year-old African-American female financial analyst is referred to you for asthma exacerbation. She reports shortness of breath with frequent expectoration of brownish plugs. Albuterol inhalers are only minimally helpful. She has had hemoptysis in the past. Temperature is 38.3 C. Chest with minimal wheezing. Her serum total IgE > 1000 ng/ml, she has a twofold elevation in specific anti- Aspergillus fumigatus IgE and IgG. Case Which of the following should you recommend? A. Albuterol nebulizers every six hours B. Prednisone taper over 3-6 months C. Voriconazole D. Itraconazole Case Which of the following should you recommend? A. Albuterol nebulizers every six hours B. Prednisone taper over 3-6 months C. Voriconazole D. Itraconazole 1
2 Allergic bronchopulmonary Aspergillosis (ABPA) Hypersensitivity reaction to noninvasive Aspergillus in the airways Repeated inflammation and mucoid impaction in airways can lead to bronchiectasis May affect up to 5% of asthma patients Mild bronchiectasis Allergic Bronchopulmonary Aspergillosis (ABPA). Rx: Steroids ± itraconazole Pulmonary Aspergilloma. Rx: Surgery ± itraconazole Invasive Aspergillosis. Rx: Voriconazole or posaconazole or caspofungin or amphotericin Case A You see a 32 year old woman with AML in your office with low grade fevers to 101, hemoptysis and increasing subcutaneous nodules 2
3 Case What would you do at this time? A. Admit B. Fine needle aspiration C. FNA and admit D. Voriconazole and return to clinic if worse She becomes acutely short of breath after receiving some blood products CXR HD#2 3
4 Aspergillus fumigatus SFGH mycology 10/00 Epidemiology Aspergillus: Risk Factors Diagnosis % Bone marrow transplant Autologous 7 Allogenic 25 Hematologic disease Leukemia/Lymphoma 29 Solid organ transplant 9 AIDS 8 Solid organ tumor 4 Chronic granulomatous disease 2 Other pulmonary disease 9 Epidemiology Aspergillus: Outcomes: Mortality Risk group Fatality rate (%) Bone marrow transplant (BMT) 87 Leukemia/Lymphoma 49 AIDS 86 Neutropenia (<500/mm 3 ) 51 CNS/disseminated 88 Pulmonary 59 Overall 58 Lin S, et al. Clin Infect Dis. 2001; 32: (Review of 1941 pts from 50 studies) 4
5 Medical Mycology: The Last 50 Years # of drugs L-AmB ABCD ABLC Terbinafine 5-FC Itraconazole Fluconazole Miconazole Ketoconazole Halo sign Treatment Voriconazole: Global Comparative Aspergillosis Study Voriconazole +/- OLAT Amphotericin B +/- OLAT Probability of Survival Survival at wk 12 VORI OLAT 70.8% AmB OLAT 57.9% Hazard ratio = 0.59 ( 95% CI ) Number of Days of Treatment Dismukes WE, Clin Infect Dis 2006; 42: Herbrecht et al. NEJM 2002: 347 OLAT: Other Licenced Antifungal Therapy 5
6 Question Which of the following is voriconazole not associated with? Voriconazole Cancer A. Seeing white flashes B. Seeing Star Wars characters C. Skin cancer D. Renal toxicity Arch Dermatol. 2010;146(3): J Am Acad Dermatol Jan;62(1):31-7 Voriconazole available Aspergillus Allergic Bronchopulmonary Aspergillosis (ABPA). Rx: Steroids ± itraconazole Pulmonary Aspergilloma. Rx: Surgery ± itraconazole Invasive Aspergillosis. Rx: Voriconazole or posaconazole or caspofungin or amphotericin Kontoyiannis et al, JID,
7 B Midwest, SE USA; Central and South America, Africa Lung (most common), dissemination to skin (like basal cell CA), bones Blastomycosis Itraconazole is drug of choice for blastomycosis Amphotericin B Prior to 1980s, amphotericin B was drug of choice. Cure rates up to 97% with 2g total dose. Significant toxicity. Azoles have replaced amphotericin B as therapy of choice Itraconazole cure rates 90-95%. Less toxic than ketoconazole and amphotericin. Few relapses. Dismukes WE et al, Am J Med 1992; 93: Ohio and Mississippi River Valleys; Central and South America; Bird and bat droppings Lung (most common), dissemination, hepatosplenomegaly, oral ulcers Histoplasmosis 7
8 Itraconazole is drug of choice for most with histoplasmosis Amphotericin B Prior to 1980s, amphotericin B was drug of choice. Cure rates up to % depending on disease. Significant toxicity. Azoles have replaced amphotericin B as therapy of choice Itraconazole cure rates 90-95%. Less toxic than ketoconazole and amphotericin. Few relapses. Dismukes WE et al, Am J Med 1992; 93: Mexico, south to Argentina Lungs, painful mouth ulcers, skin, can mimic TB Males >>> females Paracoccidiodomycosis 49 year-old gardener comes to see you in clinic with a progressive rash 1 week ago noticed a papule on the 4 th finger which ulcerated Now more nodular lesions have developed proximally Case Case After no help with multiple courses of antibiotics, what is your next step? A. More antibiotics B. Empiric antifungals C. Referral for biopsy D. Reassurance 8
9 Worldwide Contact with soil or decaying wood; gardening Begins as a hard nontender subcutaneous nodule then more nodules along lymphatics; can disseminate Sporotrichosis C Case 25 year-old Filipino- American runner comes to see you in clinic with fevers, cough, malaise for 4 weeks No help with azithromycin for a 5 day course, followed by levofloxacin Family lives in the Central Valley, California, and the patient visits often Southwest USA, Mexico, Central and South America Flu-like illness, lung, dissemination to CNS (meningitis), bone, skin Erythema nodosum in some Coccidioidomycosis 9
10 Dramatic increase in Valley Fever CDC looked at incidence of coccidioidomycosis from Incidence increased from 5 cases per 100,000 in 1998 in endemic area to 43 cases per 100,000 <1% have disseminated disease but >40% require hospitalization Fresno dust storm Coccidioidomycosis MMWR 2013 Cocci for 7 years with severe exacerbation in January Rx: amphotericin B 2.4 g orally per day. Fiese MJ. Proc Symp Cocci, Phoenix, Feb 11-13, 1957 & Cal Med 1957; 86: Pre-Rx post 3 mos RX 10
11 Itraconazole and Fluconazole are both effective for cocci Amphotericin B was drug of choice for 50 years with cure rates up to 70%. No clinical trials Use as initial treatment for severely ill C Itraconazole cure rates 63-75%. Preferred azole for skeletal disease. Galgiani JN et al, Ann Intern Med 2000; 133: Fluconazole cure rates 50-67%. Preferred azole for meningitis. Treat for life. Galgiani JN et al, Ann Intern Med 2000; 133: Worldwide Soil and dried pigeon dung Lung, dissemination in immunocompromised hosts (skin, CNS); most common cause of fungal meningitis Can be first AIDS-defining illness Cryptococcosis Use amphotericin plus flucytosine in AIDS patients with crypto Earlier studies showed lower dose of amphotericin (0.4mg/kg/day) plus 5-FC (150mg/kg/day) for 6 weeks cured 67% non-hiv Bennett JE et al, N Engl J Med 1979; 301: First AIDS studies (RCT) showed amphotericin (same dose) vs fluconazole monotherapy for 10 weeks only successful in 40% vs 34% (P=NS) Saag MS et al, N Engl J Med 1992; 326:
12 Use amphotericin plus flucytosine in AIDS patients with crypto Amphotericin (0.7mg/kg/day) plus 5-FC (100mg/kg/day) vs amphotericin X 2 weeks. CSF neg in 60% vs 51% (P=0.06). No difference in mortality (overall 5.5%). then Fluconazole (400mg/day) vs. itraconazole (400mg/day) X 8 weeks. Overall mortality 3.9%. No difference in CSF sterilization. Van der Horst et al, N Engl J Med 1997; 337:15-21 Other key crypto studies Maintain AIDS patients on fluconazole 200mg PO daily Relapse 4% (FLU) vs 23% (ITRA) Saag MS et al, Clin Infect Dis 1999; 28:291-6 Mortality associated with opening pressure >250mmHg 21% <250, 27% , 38% >350mmHg Graybill JR et al, Clin Infect Dis 2000; 30:47-54 Stop maintenance if CD4>100 on HAART (6 mo) Vibhagool A et al, Clin Infect Dis 2003; 36: Case 31 year old with AIDS CD4 157, VL<40 with headaches 12
13 Cryptococcus immune reconstitution inflammatory syndrome (IRIS) Can occur in up to 30% of patients with a history of cryptococcus after starting HAART Usually within 30 days after initiating HAART Can have higher CSF cryptococcal antigen titers and opening pressures Usually treated with amphotericin followed by fluconazole Treatment outcomes better in IRIS Shelburne SA et al, Clin Infect Dis 2005; 40:1049 Haddow LJ et al, Lancet ID 2010; 10:791 Cryptococcus gattii Clinical Infectious Diseases 2009;49: Compared to C. neoformans, C. gattii occurs in immunocompetent and has more brain lesions Case C A 43 year-old previously healthy woman sees you in clinic s/p discharge from the hospital for bowel perforation repair She was treated with broad-spectrum antibiotics for two weeks then discharged You note that the patient is febrile with T39, HR 130, BP 120/80 13
14 Question Which of the following organisms would you most be worried about as you prepare the ED accepting physician with the sign out? A. Candida albicans B. Candida non-albicans spp C. Citrobacter D. Coagulase negative Staphylococcus Epidemiology Candidemia Candida now the 4 th most common isolate recovered from blood cultures in the US Half of all Candida infections occur in surgical ICUs Transmission can occur from patient to patient and from health care worker to patient Significant shift in infection caused by nonalbicans spp of Candida Nosocomial Bloodstream Infections in 49 US Hospitals UCSF The SCOPE* Program ( ) No. of Crude Rank Pathogen Isolates % Mortality (%) 1 Coagulase-negative staphylococci Staphylococcus aureus Enterococci Candida species * Surveillance and Control of Pathogens of Epidemiologic Importance. Adapted with permission from Edmond et al. Clin Infect Dis. 1999;29: Azarbal F et al,
15 Epidemiology Candidemia: Risk Factors Use of antibiotics Indwelling catheters Hyperalimentation Cancer chemotherapy Immunosuppressive rx post-transplant ICU hospitalization Candiduria Colonization with Candidal spp Candida spectrum Oral Esophageal Vaginal, Balanitis Candidemia Other: Eye, Spleen, Liver, Endocarditis Not usually: Lungs, Urine Macular abscess with string of pearls inferiorly. Vose M et al. Postgrad Med J 2001;77: Copyright The Fellowship of Postgraduate Medicine. All rights reserved. 15
16 Candida Infection (non bloodstream) Treatment pearls Don t routinely prophylax (resistance may develop) For treatment, fluconazole 100mg po qd If no response, can use up to 800mg/day Alternatives: itraconazole po 200mg/day, voriconazole po 200mg/day, amphotericin IV 0.3 mg/kg/day, caspofungin 70mg IV X 1 then 50mg IV qd. D Bartlett J and Gallant JE. Medical Management of HIV Infection, 2006 ed. 16
17 17
18 Dermatophyte pearls Scrape your patient s skin and add KOH to the slide Most dematophytes can be treated by topical antifungals or oral agents (terbinafine, fluconazole, itraconazole) except oral medication will be needed for tinea capitis and tinea versicolor Treatment is generally for 2-4 weeks (1 dose usually enough for tinea versicolor) 18
19 Patient with meningitis 19 days following epidural steroid injection at an ambulatory surgery center Lab calls you about this weird fungus What is this? Bonus case Question Which of the following has been in the news as the main organism associated with injection of epidural steroids? A. Aspergillus B. Exserohilum C. Rhizopus D. Candida Exserohilum meningitis, United States Multistate outbreak of fungal meningitis associated with three lots of preservativefree methylprednisolone acetate (80mg/ml) from the New England Compounding Center (NECC) that were recalled on September 26, The potentially contaminated injections were given starting May 21, CDC 10/23/13. Dermatiaceous (pigmented) mould Lives on grass and in soil Can cause disease in immunocompetent In vitro susceptibility to Amphotericin B, voriconazole, itraconazole, caspofungin CDC recommends voriconazole +/ lipsosomal Amphotericin B Exserohilum what? 19
20 Case Z Patient with DKA, renal failure, immunosuppressed Black necrotic lesions of nose with invasion Broad, branching, nonseptate hyphae Almost 100% mortality in immunosuppressed Rx: Surgery and Ampho Zygomycosis Fungus Mortality Risk group Fatality rate (%) Aspergillosis Non-Aspergillus hyalohyphomycetes 80 (Scedosporium spp, Fusarium spp) Zygomycosis 100 (Rhizopus, Mucor) Phaeohyphomycosis 20 Candida 29 Zygomycosis Hussain et al, CID 2003:37 Pappas, ICAAC
21 Voriconazole available ABCD and Z Kontoyiannis et al, JID, 2005 Take home points - Aspergillus Aspergillus can cause a spectrum of disease Think of ABPA in patient with wheezing and refractory disease Treatment of choice for ABPA is steroids Invasive Aspergillosis is a rare disease but is important to recognize patients at risk Voriconazole is the most effective agent for invasive disease Important complications seen with voriconazole Amphotericin will also work but limited by toxicity Key challenge in the future remains better diagnostic strategies Take home points Blasto and others Think of geography and epidemiology in your patients with strange pulmonary and skin findings: Blastomycosis: Histoplasmosis: Penicillium marneffei: Sporotrichosis: 21
22 Take home points - Cocci Take home points - Crypto Increasing in incidence so coming soon to a clinic near you Think of coccidioidomycosis in a person from an endemic area with a pneumonia that is not improving with antibiotics Disseminated disease to bones and CNS can occur Latinos, Asians particularly at risk for disseminated disease Low threshold to call your favorite ID consultant for help May be the most common AIDS defining illness in some parts of the world Use Amphotericin and 5- FC as first line therapy in patients with AIDS Watch out for cryptococcal IRIS, especially in patients with a history of cryptococcal meningitis put on ART Most cases of cryptococcal IRIS occur within 4 weeks after starting ART Take home points - Candida Infections due to Candida species are the most common fungal infections There is a broad range of infections possible from oral thrush to invasive candidiasis that may involve any organ Candidal spp are the 4 th most frequent cause of nosocomial bloodstream infections but comprise a disproportionate mortality (40%) Early recognition is key think of the risk factors of candidiasis There has been a recent trend of non-albicans spp Take home points Dermatophytes Scrape your patient s skin and add KOH to the slide Most dematophytes can be treated by topical antifungals or oral agents (terbinafine, fluconazole, itraconazole) except oral medication will be needed for tinea capitis and tinea versicolor Treatment is generally for 2-4 weeks (1 dose usually enough for tinea versicolor) 22
23 Take home points - Zygomycosis Invasive Zygomycosis is a rare but fatal disease and is increasing Voriconazole is not effective. Only amphotericin as backbone Traditional risk group: DKA, now BMT and other transplant patients Diagnosis is tough like all the invasive mycoses. Get a biopsy Key challenge in the future remains better diagnostic strategies 23
Common Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationFungal biology. Fungal Infections. Fungal cell structure. Pathogenesis
Fungal Infections Once exotic and rare; now increasingly common Fungi are not virulent But they are good at taking advantage Opportunistic in many senses Fungal biology Eukaryotic (organized nucleus and
More informationFungal biology. Pathogenesis. Fungal cell structure. Fungal Infections MID 25 & 26. Eukaryotic (organized nucleus and cell structure) Non-motile
Fungal Infections Once exotic and rare; now increasingly common Fungi are not virulent But they are good at taking advantage Opportunistic in many senses Fungal biology Eukaryotic (organized nucleus and
More informationFungal update. Liise-anne Pirofski, M.D. Albert Einstein College of Medicine
Liise-anne Pirofski, M.D. Albert Einstein College of Medicine Fungal update http://clicks.robertgenn.com/miss-potter.php http://letterfromhere.blogspot.com/2007/06/beatrix-potters-jog-trot-through.html
More informationNorth American Endemic Fungi
North American Endemic Fungi Boni Elizabeth Elewski, MD Chair Department of Dermatology University of Alabama at Birmingham James Elder Professor of Graduate Medical Education DISCLOSURE OF FINANCIAL RELATIONSHIPS
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationFungal Infections. Alessandro Diana November 22th 2007
Fungal Infections Alessandro Diana November 22th 2007 alessandro.diana@ne.ch Topics Aspergillosis Candidiasis Cryptococcosis Histoplasmosis Coccidioidomycosis Blastomyocosis Sporotrichosis Pneumocystis
More informationManagement of fungal infection
Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationFungal Meningitis. Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse Bern
Fungal Meningitis Stefan Zimmerli Institute for infectious diseases University of Bern Friedbühlstrasse 51 3010 Bern Death due to infectious diseases in sub-saharan Africa Park BJ. Et al AIDS 2009;23:525
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationIntroduction. Study of fungi called mycology.
Fungi Introduction Study of fungi called mycology. Some fungi are beneficial: ex a) Important in production of some foods, ex: cheeses, bread. b) Important in production of some antibiotics, ex: penicillin
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationFungal infection in the immunocompromised patient. Dr Kirsty Dodgson
Fungal infection in the immunocompromised patient Dr Kirsty Dodgson Aims Discuss different types of fungi Overview of types of clinical infections Clinical Manifestations Fungus Includes Moulds Aspergillus
More informationEpidemiology and Laboratory Diagnosis of Fungal Diseases
Medical Mycology (BIOL 4849) Summer 2007 Dr. Cooper Epidemiology of Mycoses Epidemiology and Laboratory Diagnosis of Fungal Diseases Mycosis (pl., mycoses) - an infection caused by a fungus Two broad categories
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationAntifungal therapies differences in agents
Antifungal therapies differences in agents The basic Fungi are eukaryotes Eukaryote = an organism whose cells contain complex structures enclosed within membrane. Most Common Fungal Pathogens Dermatophytes
More informationSecond Joint Conference 0f the British HIV Association [BHIVA] and the British Association for Sexual Health and HIV [BASHH]
Second Joint Conference 0f the British HIV Association [BHIVA] and the British Association for Sexual Health and HIV [BASHH] 20-23 April 2010, Manchester Central Convention Complex SECOND JOINT CONFERENCE
More informationRheem Totah, Office H172M, Ph Office hours MWF 11:30 12:20 or by arrangement
Rheem Totah, Office H172M, Ph 206-543-9481 rtotah@uw.edu Office hours MWF 11:30 12:20 or by arrangement Date/Time Topic Readings Mon March 26 Antifungal agents Foye s Chapter 40 Wed March 28 Antifungal
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationResearch priorities in medical mycology
Research priorities in medical mycology David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Agenda How many patients are there with serious
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationAntifungal drugs Dr. Raz Muhammed
Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationTreatment of rare and emerging fungal infections. EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen
Treatment of rare and emerging fungal infections EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen Helen Sambatakou Lecturer in Medicine and Infectious Diseases, University of Athens, Greece
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationImproving Clinical Outcomes in Fungal Infection Control and Management
Improving Clinical Outcomes in Fungal Infection Control and Management DISCLAIMER The information within this CME/CE activity is for continuing education purposes only, and is not intended to substitute
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationCurrent and Emerging Azole Antifungal Agents
CLINICAL MICROBIOLOGY REVIEWS, Jan. 1999, p. 40 79 Vol. 12, No. 1 0893-8512/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Current and Emerging Azole Antifungal Agents
More informationCurrent Options in Antifungal Pharmacotherapy
Current Options in Antifungal Pharmacotherapy John Mohr, Pharm.D., Melissa Johnson, Pharm.D., Travis Cooper, Pharm.D., James S. Lewis, II, Pharm.D., and Luis Ostrosky-Zeichner, M.D. Infections caused by
More informationGeneral Pearls. What You Don t Know Can Hurt You: Infections in Transplant Recipients. Indication for hospitalization posttransplantation
General Pearls What You Don t Know Can Hurt You: Infections in Transplant Recipients Peter V. Chin-Hong, MD MAS September 24, 2010 UCSF Immunocompromised patients with infections are often sicker than
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationFungal Infections. Fungal Infections
Fungal Infection in the Immune Competent Host Steven L. Primack, MD Fungal Infection in the Immune Competent Host Steven L. Primack, MD Department of Radiology Oregon Health & Science University Fungal
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationHISTOPLASMOSIS - LABORATORY DIAGNOSIS IN VIETNAM
HISTOPLASMOSIS - LABORATORY DIAGNOSIS IN VIETNAM National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, National Institute of Infectious Diseases, Tokyo, Japan, Bach Mai hospital, Vietnam, Military
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More information3/16/16 COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS COCCIDIOIDOMYCOSIS. Selected References
10 MARCH 2006 Updated 5 June 2008 Updated 11 February 2011 Updated 4 March 2016 Herbert Boro, M.D., F.A.C.P. Selected References 1. Fiese, Marshall J. 1958. Coccidioidomycosis. Charles C. Thomas. 253 pp.
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationEpidemiology of Fungal Diseases
Lecture 2 Epidemiology of Fungal Diseases Disclaimer: This lecture slide presentation is intended solely for educational purposes. Many of the images contained herein are the property of the original owner,
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationAli Alabbadi. Sarah Jaar ... Nader
24 Ali Alabbadi Sarah Jaar... Nader Intro to Mycology *underlined text was explained in the lecture but is not found in the slides -mycology: the study of the mycoses of man (fungal infections) -less than
More informationEvidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures
Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections Presenter James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationInvasive Aspergillosis in India: Unique Challenges. Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai
Invasive Aspergillosis in India: Unique Challenges Dr Rajeev Soman Consultant Physician PD Hinduja Hospital Mumbai Aspergillus Challenges Capable of surviving & thriving in all the diverse environmental
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationEpidemiology and ecology of fungal diseases
Epidemiology and ecology of fungal diseases Healthcare Focus on: - individual - diagnosis - treatment Public Health Focus on: - population - prevention The nature of fungi Kingdom Fungi (lat. fungus, -i)
More informationDisease spectrum. IPA Invasive pulmonary aspergillosis
Aspergillus & ABPA Disease spectrum IPA Invasive pulmonary aspergillosis ABPA ABPA pathophysiology conidia of Aspergillus trapped in mucous and narrowed airways of asthmatics/cf germinate to form hyphae
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationChallenges in Management of Cryptococcal Meningitis. Yunus Moosa Department of ID NRMSM Durban
Challenges in Management of Cryptococcal Meningitis Yunus Moosa Department of ID NRMSM Durban Overview Epidemiology Pathogenesis Clinical presentation Diagnosis Prognostic factors Antifungal Treatment
More informationObjec&ves. Clinical Presenta&on
Michelle A. Barron, MD Associate Professor of Medicine Division of Infectious Diseases University of Colorado Denver Objec&ves Determine who is at risk for invasive candidiasis. Understand whether prophylaxis
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationPAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationCase 1. Background. Presenting Symptoms. Schecter Case1 Differential Diagnosis of TB 1
TB or Not TB? Case 1 Gisela Schecter, M.D., M.P.H. California Department of Public Health Background 26 year old African American male Born and raised in Bay Area of California Convicted of cocaine trafficking
More informationGUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS
GUIDELINE FOR THE MANAGEMENT OF CRYPTOCOCCAL MENINGITIS Full title of guideline Guideline for the management of cryptococcal meningitis Author Dr P Venkatesan (ID consultant) Division and specialty Medicine,
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationFungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell
Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate
More informationJudith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD
Pulmonary Cryptococcosis in Patients Without HIV Infection* Judith A. Aberg, MD; Linda M. Mundy, MD; and William G. Powderly, MD Purpose: To further elucidate the diagnostic and therapeutic approaches
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationDidactic Series. Fungal Infections: small bother to big mortality
Didactic Series Fungal Infections: small bother to big mortality Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 8/8/13 ACCREDITATION STATEMENT: University of California,
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationInteresting cases in fungal asthma
Interesting cases in fungal asthma Ritesh Agarwal MD, DM Professor of Pulmonary Medicine Postgraduate Institute of Medical Education and Research Chandigarh, India Fungal asthma Broadly defined as the
More informationnumber Done by Corrected by Doctor د.حامد الزعبي
number Fungi#1 Done by نرجس الس ماك Corrected by مهدي الشعراوي Doctor د.حامد الزعبي Introduction to Mycology -Terms: -Medical Mycology: The study of mycosis and their etiological agents -Mycosis: Disease
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationPathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens
Pathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens Cryptococcus neoformans Candida albicans Aspergillus species Pneumocystis carinii 1 Dermatophytes Named for derma skin Cause
More informationElements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi
More informationApproach to Fungal Infections
Approach to Fungal Infections Michelle A. Barron, M.D. Professor of Medicine Division of Infectious Diseases University of Colorado Denver Disclosures Research Investigation with Astellas Pharma, US I
More informationLecture 7: Mycoses Caused by Dimorphic Fungi, Part I
BIOL 4849 Medical Mycology Summer 2006 Histoplasmosis Lecture 7: Mycoses Caused by Dimorphic Fungi, Part I u Most common endemic mycotic disease in the United States u Two different varieties (actually
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationWhat You Don t Know Can Hurt You: Infections in Transplant Recipients
What You Don t Know Can Hurt You: Infections in Transplant Recipients Peter V. Chin Hong, MD MAS March 7, 2014 UC SF General Pearls Immunocompromised patients with infections are often sicker than they
More informationUpdate from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance 13
Fungal Infections Preface: Fungal Infections Luis Ostrosky-Zeichner and Jack D. Sobel xiii The Global Burden of Fungal Diseases 1 Snigdha Vallabhaneni, Rajal K. Mody, Tiffany Walker, and Tom Chiller Fungal
More informationTreatment and Prophylaxis
Treatment and Prophylaxis Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University Children s Hospital
More informationConcise Review for Primary-Care Physicians
Concise Review for Primary-Care Physicians Therapy for Fungal Infections GEORGE A. SAROSI, M.D., AND SCOTT F. DA VIES, M.D. In the past, few pharmacologie agents were available for management of fungal
More informationAntibiotics 301: Antifungal Agents
Antibiotics 301: Antifungal Agents B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 3/3 blood
More information2/18/19. Case 1. Question
Case 1 Which of the following can present with granulomatous inflammation? A. Sarcoidosis B. Necrobiotic xanthogranulma C. Atypical mycobacterial infection D. Foreign Body Reaction E. All of the above
More informationNEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003
NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATINS 20th Symposium (spring 2003) Thursday May 22nd 2003 The slides presented at this meeting are available on this site as "Web slide shows" and
More informationposaconazole, or prayers
Antifungal therapy: Polyenes, posaconazole, or prayers Michael Kleinberg, MD, PhD Associate Professor of Medicine Head, Infectious Diseases Section Marlene and Stewart Greenebaum Cancer Center University
More information